Download PDF
Pharmacopsychiatry 2004; 37(1): 1-11
DOI: 10.1055/s-2004-815468
Review
© Georg Thieme Verlag Stuttgart · New York

Atypical Antipsychotics and New Onset Diabetes mellitus

An Overview of the LiteratureD. Cohen1
  • 1Langevelderweg 27, AB Noordwijkerhout, The Netherlands
Further Information

Publication History

Received: 3.12.2001 Revised: 4.10.2002

Accepted: 20.11.2002

Publication Date:
29 January 2004 (online)

Also available at
    Permissions and Reprints

During the last few years, several case reports and studies have been published on the potential diabetes mellitus (DM)-inducing effect of some atypical antipsychotics, especially clozapine and olanzapine. The purpose of our study was to evaluate diabetogenic effects of atypical antipsychotics in the literature.

In order to give a full-scale overview, both peer-reviewed publications and oral and poster presentations on this subject were screened.

We found 27 case reports of new-onset DM for clozapine, 39 for olanzapine, 4 for risperidone, and 3 for quetiapine. Related to the year of introduction of these drugs on the market and the number of treatment days of each drug during the last 6 years in 13 western countries, Brazil, and Japan, the cases show an over-representation of cases related to olanzapine and clozapine. In the majority of cases, risk factors (DM family history, obesity, Negroid ethnicity) were present. Eighty-four percent of the cases arose in patients < 50 years, in contrast to the general population (most cases, > 50 years). Comparative epidemiological studies point in the same direction, with two studies showing no differences between the atypical drugs.

Antipsychotic agents are used often for treatment of schizophrenia, a condition that appears to be associated with DM also in untreated subjects. Some antipsychotics appear to induce new-onset diabetes mellitus. In view of the health risks of DM and the predisposition in patients with schizophrenia, it is advised to be cautious with prescription of antipsychotics that are associated with new-onset DM. Especially in predisposed patients (family history of DM, obese, Negroid ethnicity), reticence in this respect is required. Moreover, careful monitoring of weight, BMI, and glucose levels is advised both before these antipsychotics are prescribed and during treatment.

References

  • 1 ADA (American Diabetes Association). Screening for diabetes.  Diabetes Care. 2001;  24 (Suppl 1) S21-24
    PubMedGoogle Scholar
  • 2 Adams P F, Marrano M A. Current estimates for the national health interview survey, 1994. National Center for Health Statistics, Vital Health Statistics 1995
    Google Scholar
  • 3 Ai D, Roper T A, Riley J A. Diabetic ketoacidosis and clozapine.  Postgrad Med J. 1998;  74 (874) 493-494
    PubMedGoogle Scholar
  • 4 Allison D B, Casey D E. Antipsychotic-induced weight gain: a review of the literature.  J Clin Psychiatry. 2001;  62 (Suppl 7) 22-31
    PubMedGoogle Scholar
  • 5 Altschule M D, Siegel E, Mora-Castaneda F. Significance of rise in blood sugar level after injection of epinephrine in mental disease.  Arch Neurol Psychiat. 1951;  65 589-592
    PubMedGoogle Scholar
  • 6 Appel K E, Farr C B. The blood sugar reaction to insulin in psychoses.  Arch Neurol Psychiat. 1929;  21 145-148
    PubMedGoogle Scholar
  • 7 Bettinger T L, Mendelson S C, Dorson P G, Crismon M L. Olanzapine-induced glucose dysregulation.  Ann Pharmacother. 2000;  34 865-867
    CrossrefPubMedGoogle Scholar
  • 8 Bonanno D G, Davydov L, Botts S R. Olanzapine-induced diabetes mellitus.  Ann Pharmacother. 2001;  35 563-565
    CrossrefPubMedGoogle Scholar
  • 9 Braceland F J, Meduna L J, Vaichulis J A. Delayed action of insulin in schizophrenia.  Am J Psychiat. 1945;  102 108-110
    PubMedGoogle Scholar
  • 10 Brugman N J, Cohen D, de Vries R H. Diabetes mellitus after treatment with clozapine.  Ned Tijdschr Geneeskd. 2000 Feb 26;  144 (9) 437-439
    PubMedGoogle Scholar
  • 11 Cagliero E, Borba C P, Hayden D L, Schoenfeld D A, Goff D G, Henderson D C. Clozapine and olanzapine induce insulin resistance in patients with schizophrenic disorders. Poster presented at the 61st Scientific session of the America Diabetes Association Philadelphia, Pennsylvania; June 22 - 26, 2001
    Google Scholar
  • 12 Caro J, Ward A, Levinton C, Robinson K. Atypical antipsychotics and the risk of developing diabetes. Poster at the ACNP 2000, December 10 - 14, San Juan, Puerto Rico;
    Google Scholar
  • 13 Casey D E. Weight and metabolic changes with clozapine and olanzapine. Presentation at the APA 2000, May 13 - 18 Chicago, USA;
    Google Scholar
  • 14 Casey D E. Prevalence of diabetes during extended clozapine and olanzapine treatment. Poster at the ACNP 2000, December 10 - 14, San Juan, Puerto Rico;
    Google Scholar
  • 15 Cassidy F, Ahearn E, Carroll B J. Elevated frequency of diabetes mellitus in hospitilized manic-depressive patients.  Am J Psychiatry. 1999;  156 1417-1420
    PubMedGoogle Scholar
  • 16 Cavazzoni P, Baker R W, Kwong K, Hornbuckle K, Hutchins D, Jovanovic L. et al .A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States. Presentation at the 7th World Congress of Biological Psychiatry Berlin; 2001
    Google Scholar
  • 17 Charatan F BE, Bartlett N G. The effect of chlorpromazine (“Largactil”) on glucose tolerance.  J Mental Sci. 1955;  191 351-353
    PubMedGoogle Scholar
  • 18 Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with clozapine treatment.  Diabetes Care. 1999;  22 176-177 [Letter]
    PubMedGoogle Scholar
  • 19 Croarkin P E, Jacobs K M, Bain B K. Diabetic ketoacidosis associated with risperidone treatment?.  Psychosomatics. 2000;  41 369-370 [Letter]
    CrossrefPubMedGoogle Scholar
  • 20 Diabetes Atlas. 2000. International Diabetes Federation
  • 21 Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples.  Schizophr Bull. 2000;  26 (4) 903-912
    CrossrefPubMedGoogle Scholar
  • 22 Dwyer D S, Pinkofsky H B, Liu Y, Bradley R J. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells.  Prog Neuro-Psychopharmacol & Biol Psychiatry. 1999;  23 69-80
    PubMedGoogle Scholar
  • 23 Dwyer D S, Bradley R J, Kablinger A S, Freeman A M. 3rd. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment.  Ann Clin Psychiatry. 2001;  13 103-113
    CrossrefPubMedGoogle Scholar
  • 24 Dynes J B. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients.  Dis Nerv Syst. 1969;  30 341-344
    PubMedGoogle Scholar
  • 25 Felker B, Yazel J J, Short D. Mortality and medical comorbidity among psychiatric patients: a review.  Psychiatr Serv. 1996;  47 1356-1363
    PubMedGoogle Scholar
  • 26 Fertig M K, Brooks V G, Shelton P S, English C W. Hyperglycemia associated with olanzapine.  J Clin Psychiatry. 1998;  59 687-689 [Letter]
    PubMedGoogle Scholar
  • 27 Finney G OH. Juvenile onset diabetes and schizophrenia?. Lancet 1989;: 1214-1215 [Letter]
    Google Scholar
  • 28 Freeman H, Looney J M, Hoskins R G, Dyer C G. Results of insulin and epinephrine tolerance tests in schizophrenic patients and in normal patients.  Archives of Neurology and Psychiatry. 1943;  49 195-203
    PubMedGoogle Scholar
  • 29 Ganzini L, Heintz R T, Hoffman W F, Casey D E. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.  Arch Gen Psychiatry. 1991;  48 (3) 259-263
    PubMedGoogle Scholar
  • 30 Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment.  Diabetes Care. 1999;  22 1002-1003 [Letter]
    PubMedGoogle Scholar
  • 31 Gianfrancesco F, Grogg A, Mahmound R, Markowitz J, Nasrallah H. Differential effects of Antipsychotics on Type II Diabetes: Findings from a Large Health Plan Database. In Annual Meeting of the Society of Biological Psychiatry New Orleans, LA; 2001
    Google Scholar
  • 32 Glick I D, Romano S J, Simpson G, Horne R L, Weiden P, Pigott T, Bari M. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled 6-week trial. Poster at APA 2001, May 5 - 13, New Orleans, USA;
    Google Scholar
  • 33 Goldstein L E, Sporn J, Brown S. et al . New onset diabetes mellitus and diabetic keto-acidosis associated with olanzapine treatment.  Psychosomatics. 1999;  40 438-443
    PubMedGoogle Scholar
  • 34 Gu K, Cowie C C, Harris M I. Diabetes and decline in heart disease mortality in US adults.  JAMA. 1999;  281 1291-1297
    CrossrefPubMedGoogle Scholar
  • 35 Hägg S, Joelsson L, Mjorndal T. et al . Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.  J Clin Psychiatry. 1998;  59 294-299
    PubMedGoogle Scholar
  • 36 Harris M I, Flegal K M, Cowie C C. et al . Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988 - 1994.  Diabetes Care. 1998;  21 518-524
    CrossrefPubMedGoogle Scholar
  • 37 Hauptmann B, Kupsch A, Arnold G. Hyperglycemia associated with low-dose clozapine treatment. Presentation at the First Congress of the German Parkinson Society Wurzburg, Germany; 1999
    Google Scholar
  • 38 Henderson D C, Cagliero E, Gray C. et al . Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  Am J Psychiatry. 2000;  157 975-981
    CrossrefPubMedGoogle Scholar
  • 39 Hiles B W. Hyperglycemia and glycosuria following chlorpromazine therapy [Letter].  J Am Med Assoc. 1956;  162 1651
    PubMedGoogle Scholar
  • 40 IMS Healh. MIDAS. 2001
    Google Scholar
  • 41 Iqbal N, Oldan R L, Baird G, Schwartz B J, Bloy L, Bhagoji B, Simjee M S. Atypical antipsychotic-induced diabetes mellitus. Presentation at the APA 2000, May 13 - 18 Chicago, USA;
    Google Scholar
  • 42 Isakov I, Klesmer J, Masand P S. Insulin-resistant hyperglycemia induced by clozapine.  Psychosomatics. 2000;  41 373-374 [Letter]
    CrossrefPubMedGoogle Scholar
  • 43 Kamran A, Doraiswamy P M, Jane J L, Hammett E B, Dunn L. Severe hyperglycemia associated with high doses of clozapine.  Am J Psychiatry. 1994;  151 1395 [Letter]
    PubMedGoogle Scholar
  • 44 Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.  Annu Rev Med. 2001;  52 503-517
    CrossrefPubMedGoogle Scholar
  • 45 Kingsbury S J, Fayek M, Trufasiu D, Zada J, Simpson G M. The apparent effects of ziprasidone on plasma lipids and glucose.  J CLin Psychiatry. 2001;  62 (5) 347-349
    PubMedGoogle Scholar
  • 46 Kinon B J, Basson B R, Gilmore J A, Tollefson G D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.  J Clin Psychiatry. 2001;  62 92-100
    PubMedGoogle Scholar
  • 47 Koren W, Kreis Y, Duckowizny K, Prince T, Sangovici S, Sidi Y, Gur H. Lactic acidosis and fatal myocardial infarction due to clozapine.  Ann Pharmacother. 1997;  31 168-170
    PubMedGoogle Scholar
  • 48 Kostakoglu A E, Yazici K M, Erbas T, Guvener N. Ketoacidosis as a side-effect of clozapine: a case report.  Acta Psychiatr Scand. 1996;  93 (3) 217-218
    PubMedGoogle Scholar
  • 49 Koval M S, Rames L J, Christie S. Diabetic ketoacidosis associated with clozapine treatment.  Am J Psychiatry. 1994;  151 1520-1521 [Letter]
    PubMedGoogle Scholar
  • 50 Liebzeit K A, Markowitz J S, Caley C F. New onset diabetes and atypical antipsychotics.  European Neuropharmacology. 2001;  11 25-35
    CrossrefPubMedGoogle Scholar
  • 51 Lilliker S L. Prevalence of diabetes in amanic-depressive population.  Comprehensive Psychiatry. 1980;  21 270-275
    CrossrefPubMedGoogle Scholar
  • 52 Lindenmayer J P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus.  Am J Psychiatry. 1999;  156 1471 [Letter]
    PubMedGoogle Scholar
  • 53 Luna B, Feinglos M N. Drug-induced hyperglycemia.  JAMA. 2001;  286 1945-1948
    CrossrefPubMedGoogle Scholar
  • 54 Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.  J Clin Psychiatry. 1995;  56 514-518
    PubMedGoogle Scholar
  • 55 Mahmoud R, Gianfrancesco F, Grogg A, Nasrallah A H. Differential effects of antipsychotics on type II diabetes: findings from a large health plan database. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology December 10 - 14, 2000 in San Juan, Puerto Rico;
    Google Scholar
  • 56 Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment.  Diabetes Nutr Metab. 1999;  12 187-188 [Letter]
    PubMedGoogle Scholar
  • 57 McCreadie R, MacDonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J, Paterson J. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study.  Brit Medic Journal. 1998;  317 784-785
    PubMedGoogle Scholar
  • 58 McIntyre R S. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.  Can J Psychiatry. 2000;  46 273-281
    PubMedGoogle Scholar
  • 59 McKee H A, D'Arcy P F, Wilson P J. Diabetes and schizophrenia - a preliminary study.  J Clin Hosp Pharm. 1986;  11 297-299
    PubMedGoogle Scholar
  • 60 Melamed Y, Mazeh D, Elizur A. Risperidone treatment for a patient suffering from schizophrenia and IDDM.  Can J Psychiatry. 1998;  43 956 [Letter]
    PubMedGoogle Scholar
  • 61 Melkersson K I, Hulting A-L, Brismar K E. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.  J Clin Psychiatry. 1999;  60 783-791
    PubMedGoogle Scholar
  • 62 Melkersson K I, Hulting A-L, Brismar K E. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.  J Clin Psychiatry. 2000;  61 742-749
    PubMedGoogle Scholar
  • 63 Melkersson K, Khan A, Hilding A, Hulting A-L. Different effects of antipsychotic drugs on insulin release in vitro.  Eur Neuropsychopharmacol. 2001;  11 327-332
    CrossrefPubMedGoogle Scholar
  • 64 Meyer J M. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine- and risperidone-treated inpatients. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology December 10 - 14, 2000, in San Juan, Puerto Rico;
    Google Scholar
  • 65 Meyer J M. Novel antipsychotics and severe hyperlipidemia.  J Clin Psychopharmacol. 2001;  21 369-374
    CrossrefPubMedGoogle Scholar
  • 66 Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia.  Int Clin Psychopharmacol. 2001;  16 63-74
    PubMedGoogle Scholar
  • 67 Mohan D, Gordon H, Hindley N, Barker A. Schizophrenia and diabetes mellitus.  Br J Psychiatry. 1999;  174 180-181 [Letter]
    PubMedGoogle Scholar
  • 68 Mooy J M, Grootenhuis P A, de Vries H. et al . Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study.  Diabetes Care. 1995;  18 1270-1273
    PubMedGoogle Scholar
  • 69 Mukherjee S, Schnur D B, Reddy R. Family history of type 2 diabetes in schizophrenic patients.  Lancet. 1989;  1 495 [Letter]
    PubMedGoogle Scholar
  • 70 Mukherjee S, Decina P, Bocola V. et al . Diabetes mellitus in schizophrenic patients.  Compr. Psychiatry. 1996;  37 68-73
    Google Scholar
  • 71 Mundell W, Soares-Welch C. Diabetic ketoacidosis attributed to olanzapine. Poster presented at the Regional Meeting of the Midwestern section of the American Federation for Medicinal Research Chicago, IL, USA,; 2000.: Abstract: 273A
    Google Scholar
  • 72 Ober S K, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine.  Am J Psychiatry. 1999;  156 970 [Letter]
    PubMedGoogle Scholar
  • 73 Opp D, Hildebrandt C. Olanzapine-associated type 2 diabetes mellitus. Letter to the editor Submitted for publication
    Google Scholar
  • 74 Paizis E, Cavaleri S, Schwarz M E, Levin Z. Case report: Acute-onset diabetic ketoacidosis during olanzapine treatment in a patient without pretreatment obesity or treatment-associated weight gain.  Primary Psychiatry. 1999;  6 37-38
    PubMedGoogle Scholar
  • 75 Peterson G A, Byrd S L. Diabetic ketoacidosis from clozapine and lithium cotreatment.  Am J Psychiatry. 1996;  153 737-738 [Letter]
    PubMedGoogle Scholar
  • 76 Pierides M. Clozapine monotherapy and ketoacidosis.  Br J Psychiatry. 1997;  171 90-91 [Letter]
    PubMedGoogle Scholar
  • 77 Popli A P, Konicki E P, Jurjus G J. et al . Clozapine and associated diabetes mellitus.  J Clin Psychiatry. 1997;  58 108-111
    PubMedGoogle Scholar
  • 78 Procyshyn R M, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine.  Can J Psychiatry. 2000;  45 668-669
    PubMedGoogle Scholar
  • 79 Reinstein M J, Sirotovskaya L A, Jones L E, Mohan S, Chasanov M A. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control.  Clin Drug Invest. 1999;  18 99-104
    PubMedGoogle Scholar
  • 80 Rigalleau V, Gatta B, Bannoud S, Masson M, Bourgeois M L, Vergnot V, Gin H. Diabetes as a result of atypical anti-psychotic drugs - a report of three cases.  Diabet Med. 2000;  17 484-486
    CrossrefPubMedGoogle Scholar
  • 81 Roefaro J, Mukherjee S M. Olanzapine-induced hyperglycemic nonketonic coma.  Ann Pharmacother. 2001;  35 300-302
    CrossrefPubMedGoogle Scholar
  • 82 Schultz S K, Arndt S, Ho B C. et al . Impaired glucose tolerance and abnormal movements in patients with schizophrenia.  Am J Psychiatry. 1999;  156 640-642
    PubMedGoogle Scholar
  • 83 Selke G J, Newcomer J W, Fucetola R, Cooper B PSD, Schweiger J A. Atypical antipsychotic-induced differences in glucose regulation in schizophrenia independent of differences in adiposity. Presented at 30th Annual meeting of the Society for Neuroscience, New Orleans, Louisiana, USA. November 4 - 9, 2000.  Abstract: Society for Neuroscience. 2000;  26 275, no. 97.11
    PubMedGoogle Scholar
  • 84 Selva K A, Scott S M. Diabetic ketoacidosis associated with olanzapine in an adolescent patient.  J Pediatr. 2001;  138 936-938
    CrossrefPubMedGoogle Scholar
  • 85 Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis.  Aust N Z J Psychiatry. 1999;  33 120-121 [Letter]
    PubMedGoogle Scholar
  • 86 Sobel M, Jaggers E D, Franz M A. New-onset diabetes mellitus associated with the initiation of quetiapine treatment.  J Clin Psychiatry. 1999;  60 556-557 [Letter]
    PubMedGoogle Scholar
  • 87 Thompson J, Chengappa K N, Good C B, Baker R W, Kiewe R P, Bezner J, Schooler N R. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment.  Int Clin Psychopharmacol. 1998;  13 95-98 [Letter]
    PubMedGoogle Scholar
  • 88 Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women.  Am J Psychiatry. 1968;  124 978-982
    PubMedGoogle Scholar
  • 89 Von Hayek D, Huttl V, Reiss J, Schweiger H D, Fuessl H S. Hyperglykämie und Ketoazidose unter olanzapin.  Nervenarzt. 1999;  70 836-837
    CrossrefPubMedGoogle Scholar
  • 90 Wehring H, Alexander B, Perry P J. Diabetes mellitus associated with clozapine therapy.  Pharmacotherapy. 2000;  20 844-847
    CrossrefPubMedGoogle Scholar
  • 91 WHO . Definition, diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization Geneva,; 1999
    Google Scholar
  • 92 Wilson D R, Hammond C, Sarkar N. New-onset diabetes and ketoacidosis with atypical antipsychotics. Presented at the International Congress on Schizophrenia Research April 28 - May 2, 2001, Whistler, British Columbia, Canada;
    Google Scholar
  • 93 Winokur A, Maislin G, Phillips J L, Amsterdam J D. Insulin resistance after oral glucose tolerance testing in patients with major depression.  Am J Psychiatry. 1988;  145 325-330
    PubMedGoogle Scholar
  • 94 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes.  Biol Psychiatry. 1998;  44 778-783
    CrossrefPubMedGoogle Scholar
  • 95 Wirshing D A, Pierre J M, Eyeler J, Weinbach J, Wirshing W C. Risperidone-associated new-onset diabetes.  Biol Psychiatry. 2001;  50 148-149
    CrossrefPubMedGoogle Scholar
  • 96 Wu G, Dias P, Chun W, Li G, Kumar S, Singh S. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine.  Prog Neuropsychopharmacol Biol Psychiatry. 2000;  24 1395-1400
    CrossrefPubMedGoogle Scholar
  • 97 Yazici K M, Erbas T, Yazici A H. The effect of clozapine on glucose metabolism.  Exp Clin Endocrin Diabetes. 1998;  106 475-477
    PubMedGoogle Scholar
  • 98 Zajecka J, Weisler R, Sommerville K W. Divalproex sodium vs. olanzapine for the treatment of mania in bipolar disorder. Poster at the ACNP 2000, December 10 - 14, San Juan, Puerto Rico;
    Google Scholar
  • 99 Zung A, Blumenson R, Kupchik M, Zadik Z. Are the atypical antipsychotic drugs diabetogenic? Poster presented at the 38th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Warsaw, Poland, 29 August - 1 September, 1999.  Horm Res. 1999;  51 (Suppl 2) 102
    PubMedGoogle Scholar

D. Cohen

Langevelderweg 27

2211 AB Noordwijkerhout

The Netherlands

Email: dcohen@rijngeestgroep.nl

      >